Universitaet Muenster — Sponsor Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

9 Recruiting

4 Completed trials

3 Countries active

29 Unique IMPs

100% Results reported

Phase II

Phase I

Phase III: 1 Phase II: 8 Phase I/II: 1 Phase III/IV: 1 Phase IV: 1 Phase I: 2

Oversight events:

1 temporary halt 1 urgent safety measure 1 corrective measure across 3 trials

View oversight register →

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Breast cancer 2 Diffuse large B-cell lymphoma 2 Follicular lymphoma 2 Osteosarcoma 2 Acute kidney injury 2 High-grade B-cell lymphoma 2 Neuroblastoma 2 Ewing's sarcoma 2 Glioblastoma 2 Leiomyosarcoma 1 Liposarcoma metastatic 1 Mixed-type liposarcoma 1

Top IMPs

AMINOLEVULINIC ACID HYDROCHLORIDE 3 EPCORITAMAB 2 GD2IL18CART 2 LONCASTUXIMAB TESIRINE 2 (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE 1 ANGIOTENSIN II 1 APALUTAMIDE 1 AXICABTAGENE CILOLEUCEL 1 DAROLUTAMIDE 1 GADOBUTROL 1 MAGNESIUM CHLORIDE HEXAHYDRATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, CALCIUM CHLORIDE DIHYDRATE, MALIC ACID, SODIUM ACETATE TRIHYDRATE 1 MAGNESIUM CHLORIDE HEXAHYDRATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, CALCIUM CHLORIDE DIHYDRATE, SODIUM ACETATE TRIHYDRATE 1

All trials

14 total

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not authorised

2023-509861-19-00 Phase II 1 country EPCORITAMAB; LONCASTUXIMAB TESIRINE
Evaluating the clinical effectiveness of sodium bicarbonate for critically ill patients with metabolic acidosis and acute kidney injury Recruiting

2025-523914-10-00 Phase IV 1 country MAGNESIUM CHLORIDE HEXAHYDRATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, CALCIUM CHL…
Multimodal Imaging with FAPI-PET/MRI in Breast Carcinoma-In-Situ for Detection of occult Invasive cancer (MI-CISDIR) Recruiting

2023-509860-47-00 Phase II 1 country (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
Long-term follow-up of patients treated with GD2IL18CART Recruiting

2025-521497-34-00 Phase I 1 country GD2IL18CART
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting

2023-509861-19-01 Phase II 1 country EPCORITAMAB; LONCASTUXIMAB TESIRINE
Darolutamide and bipolar androgen therapy for mCRPC patients (DaroBAT) Recruiting

2025-521051-23-00 Phase II 1 country DAROLUTAMIDE; TESTOSTERONE
Reduction of occurence of Acute Kidney Injury through administration of angiotensin II versus Noradrenaline Recruiting

2024-517771-21-00 Phase III/IV 1 country ANGIOTENSIN II
A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers Recruiting

2022-501725-21-00 Phase I 1 country GD2IL18CART
Phase I/II dose escalation trial of radiodynamic therapy (RDT) with 5-Aminolevulinic acid in patients with first recurrence of glioblastoma Recruiting

2024-517651-12-00 Phase I/II 1 country AMINOLEVULINIC ACID HYDROCHLORIDE
Phase III study comparing Trabectedin (T) versus T plus tTF-NGR to entrap T inside the tumor in patients with metastatic and/or refractory s… Recruiting

2024-516392-33-00 Phase III 1 country TTF-NGR
Study with apalutamide in patients with prostate cancer in whom the prostate has been removed who are at high risk of disease recurrence Ended

2024-511832-29-00 Phase II 2 countries APALUTAMIDE
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With Ultrasound for Sonodynamic Therapy (SDT) in Patients With Ne… Ended

2023-509238-20-00 Phase II 1 country AMINOLEVULINIC ACID HYDROCHLORIDE
Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma Ended

2024-510972-19-00 Phase II 1 country AXICABTAGENE CILOLEUCEL
Clinical safety study on 5-Aminolevulinic acid (5-ALA) in children and adolescents with brain tumors Ended

2024-517575-20-00 Phase II 2 countries AMINOLEVULINIC ACID HYDROCHLORIDE

Showing 1–14 of 14 trials

← All sponsors A–Z